Chimerix to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 03 2018 - 4:01PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing
novel antivirals to provide solutions to the growing population of
immunocompromised patients, today announced that M. Michelle
Berrey, M.D., M.P.H, President and Chief Executive Officer
of Chimerix, will present at the 36th Annual J.P.
Morgan Healthcare Conference on Wednesday, January 10,
2018 at 5:00 p.m. PT (8:00 p.m. ET) at
the Westin Saint Francis Hotel in San Francisco, CA.
A live audio webcast of the presentation will be available on
the Investor Relations section of Chimerix’s website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to
discovering, developing and commercializing medicines that improve
outcomes for immunocompromised patients. Chimerix's
proprietary lipid conjugate technology and compound library have
produced brincidofovir (BCV, CMX001); CMX157, which was licensed to
ContraVir Pharmaceuticals; and a new candidate, CMX521, the first
direct-acting antiviral in the clinic for the treatment and
prevention of norovirus. For further information, please visit
Chimerix's website, www.chimerix.com.
CONTACT:Investor Relations:
ir@chimerix.comorWill O’ConnorStern Investor
RelationsWill@sternir.com212-362-1200
Media:
Marissa Mullane-Hanify W2O Groupmmullane@w2ogroup.com
617-337-4159
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024